# Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

> **NCT06461910** · PHASE2 · RECRUITING · sponsor: **Zekuan Xu** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Cancer
- Esophagogastric Junction Adenocarcinoma

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** thymalfasin
- **DRUG:** Oxaliplatin
- **DRUG:** Tegafur

## Key facts

- **NCT ID:** NCT06461910
- **Lead sponsor:** Zekuan Xu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-14
- **Primary completion:** 2026-01-28
- **Final completion:** 2027-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06461910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06461910, "Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT06461910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*